Redmile Group LLC grew its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 4.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,560 shares of the biotechnology company’s stock after purchasing an additional 3,860 shares during the period. Redmile Group LLC owned approximately 0.35% of Aclaris Therapeutics worth $2,564,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Citigroup Inc. lifted its holdings in shares of Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,726 shares during the last quarter. UBS Group AG lifted its holdings in shares of Aclaris Therapeutics by 60.4% during the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 1,681 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Aclaris Therapeutics by 98.3% during the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 2,605 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Aclaris Therapeutics by 1,793.1% during the 2nd quarter. Bank of Montreal Can now owns 7,137 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 6,760 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its holdings in shares of Aclaris Therapeutics by 8.3% during the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 510 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

In related news, Director Andrew N. Schiff acquired 108,601 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was bought at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 16.30% of the company’s stock.

Several analysts have recently commented on the company. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 4th. ValuEngine lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 12th. JMP Securities reiterated an “outperform” rating and set a $39.00 price objective on shares of Aclaris Therapeutics in a report on Friday, September 8th. Finally, Guggenheim reiterated a “buy” rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $41.25.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/redmile-group-llc-has-2-56-million-stake-in-aclaris-therapeutics-inc-acrs.html.

Shares of Aclaris Therapeutics, Inc. (ACRS) traded up 1.34% during trading on Monday, reaching $27.98. The company had a trading volume of 203,059 shares. The firm’s market capitalization is $748.07 million. Aclaris Therapeutics, Inc. has a 1-year low of $20.15 and a 1-year high of $33.25. The firm has a 50-day moving average of $25.92 and a 200 day moving average of $27.19.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.12. Analysts expect that Aclaris Therapeutics, Inc. will post ($3.10) earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.